|
|
migo_miao LV14
发表于 20-1-2005 01:04:17
|
显示全部楼层
|
<DIR><P>Medicine genome progress</P><P> Recent report (author: Leon Henderson, M.D. ) , Genaissance (NASDAQ: Whether GNSC ) , deCODE genetics (NASDAQ CGN ),, Pharmacia (NYSE HA) and Variagenics (NASDAQ. VGNX) the research about medicine genome of several companies comparatively leads. The medicine genome is the interreaction to the individual drug response of genome (their unique DNA array ) between a patie.</P><DIR><P>Genaissance Company has already finished the registration of STRENGTH II a clinical testing. STRENGTH I designed and clinical testing of II (measure different his man drug response of the gene HAP mark ), is it measure one clinic lower cholesterol preparation , for example he man medicine to expect to be able (whether HMG coenzyme A reduce the enzyme inhibitor), human DNA influenced makes a variat.</P><DIR><P>According to what Genaissance Company said, STRENGHT and similar medicine that the common disease is designed for the schizophrenia ,etc. are tested, will get the definite gene mark , the best using and new medicine development that these marks will help the medicine.</P><DIR><P>Genaissance Company plans not to cause the clinical failing or medicine of low rate of utilization well because of patient's curative effect to some, can confirm those result of treatment a better patient especially , improve its new clinical testing , introduce to the market again. And to other tests, Genaissance Company plans to share the information of the medicine genome alone or with the cooperator , used for developing the new medicine.</P><DIR><P>The medicine genome news of other respects belongs to deCODE and Pharmacia Company, they are devoted to finding the gene change in the cardiovascular disease evolution forming an alliance, and the clinic of relevant medication reacts. DeCODE Company use their population resource and its Clinical Genome Miner mark gather the system, to confirm whether the condition of those early heart illness develop to more advanced cardiovascular system illness.This experimental data will be applied to the experiment of Pharmacia Company: Utilize the gene mark to confirm patient's good response to its cardiovascular medicine to develop . In the agreement, deCODE Company will obtain convention reward at first stage, and may obtain the licence fees of the medicine that the project will be developed and diagnosis preparation . </P><DIR><P>Variagenics Company, it is another one that pay close attention to medicine company of genome, have study correlated with forming the carcinoma of the rectum gene mutant plan outline already. As MTHFR (methylene tetrahydrofolate reductase, four hydrogen folic acid of inferior methyl reduces ) a part of the project of enzyme, should study and confirm that reflects the best one to different anticancer treatment . MTHFR project can is it lack proper care to solidify to ordinary cardiovascular disease , blood too and nerve in charge of unusual backbone person who split illness for instance,, confirm that its treatment reacts. </P><DIR><P>Numerous companies are all using medicine genome-based technologies, the essential component part as medical management. FDA is encouraged, will most likely point the life quickly , will use the medicine genome in the clinical testing. Medicine genome-based technologies will become a doctor as the best treatment routine means of patient selection finally.The drugmaker and some large-scale biotech companies are developing the genome-based technologies of home medicine. Once the application of the medicine genome is developed, the commercial mode correlating with simple homework of medicine genome will be inestimable . </P></DIR></DIR></DIR></DIR></DIR></DIR></DIR> |
|
IP卡
狗仔卡
显身卡
